PE20091592A1 - Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b - Google Patents
Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo bInfo
- Publication number
- PE20091592A1 PE20091592A1 PE2009000335A PE2009000335A PE20091592A1 PE 20091592 A1 PE20091592 A1 PE 20091592A1 PE 2009000335 A PE2009000335 A PE 2009000335A PE 2009000335 A PE2009000335 A PE 2009000335A PE 20091592 A1 PE20091592 A1 PE 20091592A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- weight
- pharmaceutical composition
- ketorolaco
- vitamins
- Prior art date
Links
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical class OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title abstract 2
- 229940088594 vitamin Drugs 0.000 title abstract 2
- 229930003231 vitamin Natural products 0.000 title abstract 2
- 235000013343 vitamin Nutrition 0.000 title abstract 2
- 239000011782 vitamin Substances 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 13
- 239000011230 binding agent Substances 0.000 abstract 2
- 229920001688 coating polymer Polymers 0.000 abstract 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229960004752 ketorolac Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN PRIMER COMPARTIMIENTO QUE COMPRENDE i) 0.2 A 6.0% DE KETOROLACO EN PESO DE LA COMPOSICION, ii) 2.5 A 60.0% DE LA VITAMINA B1 EN PESO DE LA COMPOSICION, iii) 0.05 A 1.5% DE LA VITAMINA B12 EN PESO DE LA COMPOSICION, iv) 15.0 A 60.0% DEL VEHICULO DE COMPRESIBILIDAD EN PESO DE LA COMPOSICION, v) 5.0 A 60.0% DEL AGLUTINANTE DILUENTE EN PESO DE LA COMPOSICION, vi) 0.002 A 1.0% DEL ANTIESTATICO EN PESO DE LA COMPOSICION, vii) 0.5 A 2.5% DEL DESINTEGRANTE EN PESO DE LA COMPOSICION, viii) 0.5 A 2.5% DEL LUBRICANTE EN PESO DE LA COMPOSICION, ix) 0.2 A 11.5% DEL PLASTIFICANTE EN PESO DE LA COMPOSICION; B) UN SEGUNDO COMPARTIMIENTO QUE COMPRENDE UNA CUBIERTA O CAPA AISLANTE FORMADA DE UN POLIMERO DE RECUBRIMIENTO EN UNA CANTIDAD DE 1.5 A 7.5% EN PESO DE LA COMPOSICION; C) UN TERCER COMPARTIMIENTO QUE COMPRENDE i) 2.5 A 60.0% DE PIRIDOXINA O VITAMINA B6 EN PESO DE LA COMPOSICION, E ii) 5.0 A 40.0% DE UN POLIMERO LIGANTE AGLUTINANTE EN PESO DE LA COMPOSICION. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE DOLOR O NEURALGIAS DE DIVERSA LOCALIZACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2008003230A MX2008003230A (es) | 2008-03-07 | 2008-03-07 | Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091592A1 true PE20091592A1 (es) | 2009-11-11 |
Family
ID=41055594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000335A PE20091592A1 (es) | 2008-03-07 | 2009-03-05 | Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110059171A1 (es) |
| EP (1) | EP2255803B1 (es) |
| AR (1) | AR070542A1 (es) |
| BR (1) | BRPI0908988A2 (es) |
| CA (1) | CA2717900C (es) |
| CO (1) | CO6290082A1 (es) |
| CR (1) | CR11668A (es) |
| DO (1) | DOP2010000265A (es) |
| EC (1) | ECSP10010442A (es) |
| ES (1) | ES2526359T3 (es) |
| HN (1) | HN2010001775A (es) |
| MX (1) | MX2008003230A (es) |
| PE (1) | PE20091592A1 (es) |
| PL (1) | PL2255803T4 (es) |
| WO (1) | WO2009109836A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2619344C1 (ru) * | 2016-03-01 | 2017-05-15 | Петр Александрович Попов | Способ лечения невралгии |
| TR201702630A2 (tr) | 2017-02-22 | 2018-09-21 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Alfa li̇poi̇k asi̇t ve suda çözünür vi̇tami̇nler i̇çeren oral farmasöti̇k bi̇leşi̇mler |
| EP3366291A1 (en) * | 2017-02-22 | 2018-08-29 | Montero Gida Sanayi Ve Ticaret A.S. | Solid oral pharmaceutical compositions comprising alpha lipoic acid and water-soluble vitamins |
| CA3199162A1 (en) * | 2020-12-04 | 2022-06-09 | Cecilia Jannette Munoz Martinez | Fixed-dose combination drug for the control and management of neuropathic pain |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4492M (es) * | 1965-07-07 | 1966-10-10 | ||
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| US5382591A (en) * | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
| US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
| US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US9668972B2 (en) * | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| MXPA02010828A (es) * | 2002-11-04 | 2004-07-16 | Leopoldo Espinosa Abdala | Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor. |
| US7335384B2 (en) * | 2006-03-17 | 2008-02-26 | 4K Nutripharma International | Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith |
| DOP2007000055A (es) * | 2006-04-10 | 2007-10-31 | Senosiain S A De C V Lab | Composición farmaceutica que comprende un analgésico y vitaminas |
-
2008
- 2008-03-07 MX MX2008003230A patent/MX2008003230A/es active IP Right Grant
-
2009
- 2009-02-27 AR ARP090100696A patent/AR070542A1/es unknown
- 2009-03-04 PL PL09717937T patent/PL2255803T4/pl unknown
- 2009-03-04 EP EP09717937.8A patent/EP2255803B1/en not_active Not-in-force
- 2009-03-04 US US12/921,317 patent/US20110059171A1/en not_active Abandoned
- 2009-03-04 WO PCT/IB2009/000413 patent/WO2009109836A1/es not_active Ceased
- 2009-03-04 BR BRPI0908988-8A patent/BRPI0908988A2/pt not_active Application Discontinuation
- 2009-03-04 CA CA2717900A patent/CA2717900C/en not_active Expired - Fee Related
- 2009-03-04 ES ES09717937.8T patent/ES2526359T3/es active Active
- 2009-03-05 PE PE2009000335A patent/PE20091592A1/es active IP Right Grant
-
2010
- 2010-09-01 DO DO2010000265A patent/DOP2010000265A/es unknown
- 2010-09-02 EC EC2010010442A patent/ECSP10010442A/es unknown
- 2010-09-02 CR CR11668A patent/CR11668A/es unknown
- 2010-09-03 CO CO10109151A patent/CO6290082A1/es active IP Right Grant
- 2010-09-07 HN HN2010001775A patent/HN2010001775A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR070542A1 (es) | 2010-04-14 |
| CA2717900C (en) | 2016-05-10 |
| CA2717900A1 (en) | 2009-09-11 |
| ECSP10010442A (es) | 2010-10-30 |
| BRPI0908988A2 (pt) | 2020-08-04 |
| WO2009109836A1 (es) | 2009-09-11 |
| MX2008003230A (es) | 2009-09-07 |
| EP2255803A4 (en) | 2011-06-29 |
| EP2255803B1 (en) | 2014-09-17 |
| CR11668A (es) | 2010-11-30 |
| CO6290082A1 (es) | 2011-06-20 |
| DOP2010000265A (es) | 2010-09-30 |
| EP2255803A1 (en) | 2010-12-01 |
| ES2526359T3 (es) | 2015-01-09 |
| PL2255803T3 (pl) | 2015-05-29 |
| HN2010001775A (es) | 2013-01-15 |
| PL2255803T4 (pl) | 2015-05-29 |
| US20110059171A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172157A (en) | Thioninium compounds and their use | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| CL2007001734A1 (es) | Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
| CL2012000702A1 (es) | Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson. | |
| WO2008144061A3 (en) | Novel combinations comprising a phosphodiesterase-5 inhibitor and their use | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
| PE20090168A1 (es) | Composiciones farmaceuticas de buprenorfina y naloxona | |
| BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
| AR051397A1 (es) | Composicion farmaceutica | |
| MX2009011862A (es) | Composiciones farmaceuticas de administracion oronasofaringea de agonistas de la dopamina para la prevencion/alivio y/o tratamiento del desorden de miembros inquietos. | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
| AR123542A2 (es) | Compuesto inhibidor de iap, método in vitro para inhibir la unión de una proteína iap con una proteína caspasa y método in vitro de sensibilización de una célula a una señal de apoptosis | |
| EA201270226A1 (ru) | Витамин d3 и его аналогии для лечения алопеции | |
| MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
| WO2012001065A3 (en) | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor | |
| GT201200348A (es) | Composiciones farmacèuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona | |
| BRPI0816814A2 (pt) | composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação. | |
| CL2008000303A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion. | |
| TW200800987A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| PE20091592A1 (es) | Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b | |
| CL2007001945A1 (es) | Compuestos derivados de alquilpiridazina, inhibidores de 11 beta-hsd1; proceso de obtencion de los compuestos; composicion farmaceutica que los comprenden; y usos en el tratamiento de la diabetes, obesidad, trastorno de ingestion de comida, dislipide | |
| CL2009002129A1 (es) | Derivados carboxiamida de lantibioticos; proceso de preparacion de dichos lantibioticos; composicion farmaceutica que lo contiene; utiles en el tratamiento de infecciones bacterianas. | |
| CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |